BLUE News
Archived Headlines
- US IPO Recap: Textura and LightInTheBox gain over 30%, eight companies file 06/10/13
- Gene therapy biotech bluebird bio sets terms for $75 million IPO 06/04/13
- US IPO Recap: Marketo and Tableau soar, May calendar stays full 05/20/13
- Gene therapy biotech bluebird bio files for a $86 million IPO 05/14/13
Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues
Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics (NASDAQ: PTIE) rose 82.3% in its July 2000 debut. The...read more
US IPO Recap: Biotech success continues, but three deals delayed or postponed
Three companies priced US IPOs last week, while one was delayed and two, including Votorantim Cimentos (VEBM), the largest expected deal of 2013 year-to-date, were postponed. Two biotechs, bluebird bio (BLUE) and PTC Therapeutics (PTCT), priced upsized...read more
bluebird bio prices upsized IPO above the range at $17
bluebird bio, a clinical-stage biotech developing gene therapies for severe genetic and orphan diseases, raised $101 million by offering 5.9 million shares at $17, above the range of $14 to $16. The company had originally planned to offer 5.0 million shares....read more
6 US IPOs planned for the week of Jun 17
The following IPOs are expected to price this week: Aratana Therapeutics (PETX), which is developing medications for cats and dogs based on therapies for humans, plans...read more